Cytek Biosciences ($NASDAQ:CTKB) is a leading biotechnology company that focuses on developing, manufacturing and marketing innovative immunoassay systems. The company has been at the forefront of immunoassay technology for over two decades, specializing in providing products for clinical and research-based applications. On Tuesday, August 8th, Cytek Biosciences will be releasing its quarterly earnings results after the close of the market. By releasing their financial results, the company will be providing investors and analysts with an insight into the performance of the company for the previous quarter.
Analysts anticipate that the results will help to provide a clearer picture of the financial position of the company going forward. As such, the release of the results on Tuesday is likely to influence the price of Cytek Biosciences stock on the day, potentially resulting in significant movement in the stock price. Investors and analysts may also take into account any news or announcements that are made alongside the earnings report.
In their most recently reported earning report of FY2023 Q1 ending March 31 2021, CYTEK BIOSCIENCES earned a total revenue of 24.27M USD and a net income of 0.1M USD. Compared to the same quarter in the previous year, there was a 30.8% decrease in total revenue and a 105.0% decrease in net income. During the last 3 years, the company’s total revenue has grown from 24.27M USD to 37.09M USD. With the upcoming quarterly report release, investors and analysts alike will be closely watching to see the company’s progress.
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Cytek Biosciences. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Cytek Biosciences. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Cytek Biosciences. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Cytek Biosciences are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
On Monday, the company’s stock opened at $9.1 and closed at $9.2, representing an increase of 0.9% from the previous day’s closing price. Investors remain hopeful for the company’s prosperity as CYTEK BIOSCIENCES continues to expand its international reach. The general consensus is CYTEK BIOSCIENCES has the potential to continue its positive performance, and the quarterly earnings report may provide an indication of whether or not that potential is being realized. Live Quote…
Analysis – Cytek Biosciences Stock Fair Value Calculation
We at GoodWhale recently conducted a detailed analysis of CYTEK BIOSCIENCES’s wellness. Based on our proprietary Valuation Line, we calculated that the intrinsic value of the company’s share is $15.8. Currently, the stock is traded at $9.2, which means it is undervalued by 41.8%. This presents a great opportunity for investors to buy the stock at a significant discount. More…
Risk Rating Analysis
Star Chart Analysis
Its competitors are Pressure BioSciences Inc, Delcath Systems Inc, Longport Inc.
– Pressure BioSciences Inc ($OTCPK:PBIO)
Pressure BioSciences Inc is a biotechnology company that develops, manufactures, and markets systems and consumables for sample preparation and analytical techniques used in the life sciences industry. The company’s products are based on the pressure cycling technology, which is a method of applying alternating cycles of hydrostatic pressure between ambient and ultra-high levels to biological samples in order to open or lyse cells and archives, release their contents for further analysis.
Delcath Systems Inc. is a commercial-stage pharmaceutical company focused on the treatment of primary and metastatic liver cancers. The Company’s product, Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS), is an investigational drug delivery system that is designed to administer very high-dose melphalan, a chemotherapeutic agent, to the liver while minimizing exposure of other normal tissues.
Investors are keeping an eye on Cytek Biosciences earnings results for the quarter ending on August 8th. Analysts are predicting a very positive outcome, with estimates of revenue and earnings exceeding the company’s last quarter results. The company’s focus on immuno-oncology, genomics, and diagnostics may be key drivers to its success.
Investors should watch for improvement in margins, and increased demand for its products, both of which would be signs of increased profitability. Other metrics such as cash flow and debt-equity ratio should also be monitored.